Navigation Links
Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
Date:11/25/2013

BETHESDA, Md., Nov. 25, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, has completed an underwritten public offering of 4,895,834 units at a public offering price of $4.80 per unit, resulting in gross proceeds of $23,500,000.  Northwest also announced today that the underwriter has exercised in full its option to purchase an additional 734,374 units to cover over-allotments. Exercise of the over-allotment option increases the gross proceeds to the Company to $27,025,000.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Each unit consists of one share of common stock, and a warrant to purchase 0.5 shares of common stock at an exercise price of $6.00 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.

Oppenheimer & Co. Inc. served as the sole book-running manager for the offering.

The securities described were offered pursuant to a shelf registration statement (File No. 333-185898), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 5, 2013.  A prospectus supplement and an accompanying prospectus relating to the offering was filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com, or by accessing the SEC's website at www.sec.gov.  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. 

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, including risks related to the Company's use of the offering proceeds, the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
2. Chicago Man Breathes Again Thanks to Northwestern Medicine Study
3. Inaugural Obliteride Sets Northwest Fundraising Record
4. MinuteClinic Signs Clinical Collaboration with Baptist Health Care for Clinic Locations in Three-County Region of Northwest Florida
5. Northwestern Medicine Researchers Investigate New Stent Technology to Treat Coronary Artery Disease
6. Northwest Biotherapeutics Announces Registered Direct Offering
7. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
8. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
9. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
10. Northwest Bio Awarded $5.5 Million German Government Grant
11. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 2017 Viverae ® , a leader in ... of IBM ® Watson Campaign Automation, implementing behavioral ... for a personalized experience. Through digital engagement, the platform ... in real time. The enhanced experience drives engagement by ... wherever they are in their journey to health. ...
(Date:4/18/2017)... April 18, 2017  Astute Medical, Inc., developer of ... to be presented at the 2017 National Kidney Foundation ... and continues through April 22. Physicians will present data ... to assess risk for acute kidney injury (AKI) during ... (ADHF). Elevated levels of TIMP-2 and ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after ... pick in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl ... rushing yards by a quarterback (6,109) and the most rushing yards by a quarterback ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director ... Communication of Education Research Award. The award honors scholars exemplary in their capacity ... a scholar who has demonstrated the capacity to deepen the public’s understanding and ...
(Date:4/24/2017)... ... 24, 2017 , ... Sean Fay is the undisputed king of the infomercial. ... and the George Foreman Grill (which sold more than 100 million units worldwide), he ... years. , Now, due to changes in the broadcast media landscape, the once ever-present ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... that they are seeking public support to bring their novel lifesaving device for ... wearable device packed with medical-grade sensors, specially designed to read a child’s vital ...
Breaking Medicine News(10 mins):